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Abstract 
In this study, the Plaque SimulatorTM eye plaque brachytherapy planning system was commissioned for 
ROPES eye plaques and Amersham Health model 6711 Iodine 125 seeds, using TG43-UI data. The 
brachytherapy module of the RADCALC® independent checking program was configured to allow 
verification of the accuracy of the dose calculated by Plaque SimulatorTM. Central axis depth dose 
distributions were compared and observed to agree to within 2% for all ROPES plaque models and depths 
of interest. Experimental measurements were performed with a customized PRESAGEm 3-D type 
dosimeter to validate the calculated depth dose distributions. Preliminary results have shown the effect 
of the stainless steel plaque backing decreases the measured fluorescence intensity by up to 25%, and 
40% for the 15 mm and 10 mm diameter ROPES plaques respectively. This effect, once fully quantified 
should be accounted for in the Plaque SimulatorTM eye plaque brachytherapy planning system. 
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Abstract. In this study, the Plaque SimulatorTM eye plaque brachytherapy planning system was 
commissioned for ROPES eye plaques and Amersham Health model 6711 Iodine 125 seeds, 
using TG43-UI data. The brachytherapy module of the RADCALC® independent checking 
program was configured to allow verification of the accuracy of the dose calculated by Plaque 
SimulatorTM. Central axis depth dose distributions were compared and observed to agree to 
within 2% for all ROPES plaque models and depths of interest. Experimental measurements 
were performed with a customized PRESAGEm 3-D type dosimeter to validate the calculated 
depth dose distributions. Preliminary results have shown the effect of the stainless steel plaque 
backing decreases the measured fluorescence intensity by up to 25%, and 40% for the 15 mm 
and 10 mm diameter ROPES plaques respectively. This effect, once fully quantified should be 
accounted for in the Plaque SimulatorTM eye plaque brachytherapy planning system. 
1.  Introduction 
Choroidal melanoma is the most common primary intraocular malignancy [1] and is commonly treated 
using plaque brachytherapy, external beam charged particle therapy, surgical resection or enucleation. 
The Collaborative Ocular Melanoma Study (COMS) trial began in 1986 [2], comparing enucleation 
against a minimum of 100 Gy I-125 plaque radiation therapy for medium-sized choroidal melanomas. 
With 12 years follow up, no significant difference in survival was found, establishing eye plaque 
brachytherapy as an effective treatment modality for choroidal melanoma [3]. 
Following the publication of AAPM TG-43 report in 1995 providing a dose calculation formalism 
for Ir-192, I-125 and Pd-103 sources [4], the dose prescription of 100 Gy was lowered to 85 Gy [5]. A 
TG-43 report update was released in 2004 (TG43-UI [6]) to include new brachytherapy sources and 
critically reassessed some published brachytherapy dosimetry data, however both the TG-43 and 
TG43-UI reports assume a full water scattering medium around the sources. 
I-125 seeds have been the subject of extensive dosimetric studies using LiF thermoluminescent 
dosimeters (TLD), diodes, scintillators, Gafchromic film and polymer gels [6]. LiF TLD remains the 
method of choice recommended in the AAPM TG43-UI report [6], and Monte Carlo codes are often 
used as benchmarks for any experimental measurements [7]. 
Whilst the dosimetric studies of model 6711 I-125 seeds are extensive, many of these are limited to 
the study of the seeds in conjunction with COMS plaques [8]. To date, only one group has published a 
Monte Carlo study of the dose distributions produced by Radiation Oncology Physics and Engineering 
Services Australia (ROPES) type eye plaques with model 6711 I-125 seeds [9] and to the best of our 
knowledge, limited experimental data have been reported.  
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The Plaque SimulatorTM eye plaque brachytherapy planning system (BEBIG, Germany) was 
recently commissioned in our institution using TG43-UI data for model 6711 Amersham Health 
(London, UK) I-125 seeds in association with ROPES eye plaques. The brachytherapy module of 
RADCALC® independent checking program (Lifeline Software, Inc. USA) was used to separately 
model the ROPES eye plaques loaded with model 6711 I-125 seeds and verify the resulting treatment 
time calculation accuracy. Central axis eye plaque depth dose distributions, as calculated by Plaque 
SimulatorTM and RADCALC®, are compared for different ROPES eye plaque seed configurations. 
PRESAGE® is a radiochromic solid dosimeter 3-D dosimeter [10, 11]. Preliminary results obtained 
using customized PRESAGEm 3-D dosimeter for central axis fluorescence intensity measurements are 
also presented with an experimental assessment of the effect of the plaque backing on the distribution. 
2.  Materials & Methods 
2.1.  ROPES Eye Plaques loaded with I-125 Seeds (Amersham Health type 6711) 
The ROPES eye plaques consist of an acrylic carrier with holes for the I-125 seeds combined with a 
stainless steel backing shield to place the acrylic insert in. Available plaque diameters are 11, 15 and 
18 mm with 4, 9 or 10, and 14 seeds, respectively. The stainless steel backing and the acrylic insert are 
portion of a spherical shell that offsets the radioactive seeds by approximately 1 mm from the sclera of 
the eye [9]. The Amersham Health type 6711 I-125 seed is a cylindrically shaped and silver rod on 
which I-125 has been coated onto the surface. It emits photons with a weighted mean energy of 28.37 
keV [7].  
2.2.  Dose calculations with Plaque SimulatorTM and RADCALC® 
The Plaque SimulatorTM v5.63 software (BEBIG Germany) supports dose calculations for a variety of 
eye plaques, radioactive nuclides and seed models. The dose calculations are performed three-
dimensionally with an algorithm based on the superposition principle, using TG43-UI data and 
formalism [12].  
RADCALC® v6.1 (Lifeline Software, Inc. USA) is a versatile program designed to independently 
check radiation therapy treatment doses. The brachytherapy module allows dose calculations to points 
of interest for various brachytherapy sources whose data and model/approximation are user defined. 
The 3D I-125 seeds geometries were defined in Radcalc® for every ROPES eye plaque type available.  
The line-source approximation for the geometry function and 2D anisotropy corrections were used 
for the I-125 sources in both software systems and lead to single seed dose comparison of difference 
less than 1% at distances up to 1 cm from the seed centre. 
The plaques were loaded with 9.93 U sources and treatment times calculated in Plaque SimulatorTM 
to deliver 85 Gy to a depth of 5 mm. Corresponding treatment times were entered into RADCALC®, 
taking into account that RADCALC® does not account for the decay of the sources during treatment. 
Central axis depth dose distributions were then compared for each of the ROPES eye plaques. 
2.3.  3-D PRESAGEm Phantom/Dosimeter and irradiation protocols 
Customized 3-D PRESAGEm phantoms/dosimeters were shaped in hemispheres to match eye ball 
geometry and fit ROPES eye plaques internal curvature. The following fractional atomic-mass 
composition optimized water equivalence for low-energy photons with a resulting mass-density of 
1.06 g/cm3 (at room temperature) and Zeff=7.46: C (64.086%); N (5.083%); H (9.379%); O 
(20.922%); Sn (0.011%); Br (0.518%) [13]. 
Plaque SimulatorTM was used to calculate the time needed to deliver a dose of 3 Gy to 5 mm depth. 
ROPES plaques loaded with model 6711 I-125 seeds were then placed over the hemispherical 3-D 
PRESAGEm phantoms/dosimeters, and bound together using film wrap. The arrangement was then 
submerged in a water tank, in order to provide full scatter conditions, and left for the calculated 
treatment time. Experiments were repeated for each plaque configuration both with and without the 
stainless steel backing, in order to quantify its contribution to the central axis fluorescence signal. 
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Fluorescence intensities obtained with the 3-D PRESAGEm dosimeters were read using a laser type 
confocal microscope as described elsewhere [14]. 
3.  Results 
3.1.  ROPES Eye Plaques Dose Calculation Comparison 
Figure 1 presents the calculated percentage difference in the central axis depth dose curves between 
Plaque SimulatorTM and RADCALC® for all ROPES plaque models. Agreement better than 2% 
between the two programs is observed for depths of 1 – 8 mm, except for the 18 mm diameter eye 
plaque (14 seed insert) at a depth of 1 mm.  
 
  
Figure 1: Percentage different between Plaque SimulatorTM 
and RADCALC® for ROPES eye plaque central axis depth 
dose curves. 
Figure 2: Central axis fluorescence intensity measurements 
for the 15 mm diameter (10 seeds insert) ROPES plaque. 
3.2.  3-D PRESAGEm Central Axis Measurements 
Figure 2 shows the eye plaque central axis fluorescence intensity curves measured by the gel 
dosimeters for the 15 mm diameter plaque (10 seeds), both with and without the plaque stainless steel 
backing. The effect of the plaque backing is observed to result in a decrease in signal when compared 
to the measurements in which the plaque backing was removed, with a maximum difference of -25% 
occurring at 2 mm depth. The 10 mm plaque (4 seeds) resulted in similar signal decrease, with a 
maximum of -40% also occurring at 2 mm depth. 
4.  Discussion and Conclusion 
The Plaque SimulatorTM eye plaque brachytherapy planning system was commissioned following 
TG43-UI data and formalism for use with ROPES eye plaques and Amersham Health model 6711 I-
125 seeds. The 3D geometries for these plaques loaded with their I-125 seeds were simulated in the 
RADCALC® independent checking program to allow verification of the doses calculated by Plaque 
SimulatorTM. Central axis depth dose comparisons agreed to within 2% for all ROPES plaques seed 
configurations, except for the 18 mm diameter (14 seeds) eye plaque where a discrepancy of 2.2% is 
found at 1 mm depth. At this point, there is a superposition of a large number of sources at a short 
distance, corresponding to a region of large uncertainty in the dosimetric data. Further comparison of 
the two programs is planned in order to compare off-axis profiles at several depths of interest. Using 
these off-axis profiles, three-dimensional dose distributions can be obtained. Precise calculations of 
these dose distributions are necessary in order for Plaque SimulatorTM to accurately determine the dose 
to the sclera of the eye and other organs at risk (lens, macula, etc.). 
Preliminary central axis fluorescence intensity curves have been measured using 3-D PRESAGEm 
dosimeters. The effect of the eye plaque stainless steel backing on the shape of the curve was 
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investigated. The effect of the stainless steel plaque backing was observed to decrease the measured 
fluorescence intensity by up to 25% and 40% for the 15 mm and 10 mm diameter ROPES plaques 
respectively, and was not predicted by any of the dose calculation software systems that use water full 
scatter conditions. Granero et al. [9] have shown through Monte Carlo simulation, an average decrease 
in dose due to the stainless steel backing of the 15 mm diameter (4 seeds) eye plaque of 4%.  
Future measurements using the 3-D PRESAGEm dosimeters should be performed with a calibration 
of the gels to correlate the fluorescence intensity with dose. Also, through read-out with optical CT, 
three-dimensional dose distributions measured by the gels can be obtained to compare with dose 
distributions produced by the Plaque SimulatorTM and RADCALC® programs. The effect of the plaque 
backing on the dose distribution can then be fully quantified, and eventually, this effect incorporated 
into the Plaque SimulatorTM planning system. Corrections for inhomogeneities associated with the 
plaque backing and seed holders are plaque specific, and must be fully quantified for more accurate 
dosimetry of treatments using ROPES eye plaques. 
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